{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:50Z","timestamp":1787022110447,"version":"build-2736575974"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ecuphar\/Animalcare Group"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This prospective, multisite, blinded, randomized, non-inferiority clinical study aimed to confirm the efficacy and safety of enflicoxib in the treatment of pain and inflammation associated with canine osteoarthritis. A total of 180 dogs were randomized to receive enflicoxib (n = 78), mavacoxib (n = 80) or placebo (n = 22). Dogs underwent veterinary assessments from day 0 to day 42 using a clinical sum score (CSS). Efficacy was also assessed by the owners using the Canine Brief Pain Inventory (CBPI). The primary efficacy endpoint was the overall CSS from day 0 to day 42.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall CSS expressed as area under the curve demonstrated non-inferiority of enflicoxib compared to mavacoxib, and both showed superiority over placebo. At the end of the study, average CSS, and the percentage of CSS responders for enflicoxib (3.64 and 74%) and mavacoxib (4.49 and 68%), was superior to placebo (7.15 and 29%). A faster onset of action was observed for enflicoxib as superiority over placebo was evidenced from the first efficacy assessment (day 7) onwards for both parameters, whereas mavacoxib was only significantly different from day 14 onwards. According to the owner assessment, the percentage of CBPI responders was 90%, 79%, and 43% for dogs treated with enflicoxib, mavacoxib and placebo, respectively, and superiority over placebo was demonstrated for both active treatments. In all secondary parameters, non-inferiority of enflicoxib versus mavacoxib was confirmed. The dog\u2019s quality of life improved in all groups, but only enflicoxib showed superiority versus placebo. When assessing severely affected dogs only, results were similar, thus confirming the efficacy of enflicoxib in all stages of canine OA. There were no differences between groups in the frequency of adverse events, which were most frequently mild affecting the gastrointestinal tract and recovered without treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Enflicoxib is efficacious and safe for the treatment of pain and inflammation in any stage of canine osteoarthritis with a faster onset of action compared to mavacoxib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0274800","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T13:33:25Z","timestamp":1663680805000},"page":"e0274800","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib"],"prefix":"10.1371","volume":"17","author":[{"given":"Marta","family":"Salichs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9653-7421","authenticated-orcid":true,"given":"Lloren\u00e7","family":"Badiella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patxi","family":"Sarasola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5440-7699","authenticated-orcid":true,"given":"Josep","family":"Homedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"issue":"3","key":"pone.0274800.ref001","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2460\/javma.2005.226.387","article-title":"Estimates of prevalence of hip dysplasia in Golden Retrievers and Rottweilers and the influence of bias on published prevalence figures","volume":"226","author":"ER Paster","year":"2005","journal-title":"J Am Vet Med Assoc"},{"issue":"5","key":"pone.0274800.ref002","doi-asserted-by":"crossref","first-page":"690","DOI":"10.2460\/javma.229.5.690","article-title":"Lifelong diet restriction and radiographic evidence of osteoarthritis of the hip joint in dogs","volume":"229","author":"GK Smith","year":"2006","journal-title":"J Am Vet Med Assoc"},{"issue":"1","key":"pone.0274800.ref003","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00221-009-1782-9","article-title":"Joint pain","volume":"196","author":"HG Schaible","year":"2009","journal-title":"Exp Brain Res"},{"issue":"5\u20136","key":"pone.0274800.ref004","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.rehab.2016.07.004","article-title":"An update on the pathophysiologyof osteoarthritis.","volume":"59","author":"A Mobasheri","year":"2016","journal-title":"Ann Phys Rehabil Med"},{"key":"pone.0274800.ref005","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1038\/s41598-018-23940-z","article-title":"Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care.","volume":"8","author":"KL Anderson","year":"2018","journal-title":"Sci Rep."},{"issue":"4","key":"pone.0274800.ref006","first-page":"699","article-title":"Osteoarthritis. Joint anatomy, physiology, and pathobiology.","volume":"27","author":"SA Johnston","year":"1997","journal-title":"Vet Clin North Am Small Anim Pract."},{"issue":"3","key":"pone.0274800.ref007","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/ar3373","article-title":"Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model.","volume":"13","author":"M Moreau","year":"2011","journal-title":"Arthritis Res Ther."},{"issue":"Sup 2","key":"pone.0274800.ref008","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1016\/j.jval.2019.04.1886","article-title":"Diagnosis and treatment rates of osteoarthritis in dogs using a health risk assessment (HRA) or health questionnaire for osteoarthritis in general veterinary practice.","volume":"22","author":"A Wright","year":"2019","journal-title":"Lascelles B and Pavlock A.Value in Health"},{"key":"pone.0274800.ref009","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fvets.2020.00220","article-title":"Risk Factors for Canine Osteoarthritis and Its Predisposing Arthropathies: A Systematic Review.","volume":"7","author":"KL Anderson","year":"2020","journal-title":"Front Vet Sci."},{"issue":"1","key":"pone.0274800.ref010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.tvjl.2004.08.014","article-title":"Pharmaceutical and nutraceutical management of canine osteoarthritis: present and future perspectives.","volume":"170","author":"Y Henrotin","year":"2005","journal-title":"Vet J."},{"key":"pone.0274800.ref011","first-page":"287","article-title":"Treatment options for osteoarthritis.","volume":"11","author":"G. Singh","year":"2003","journal-title":"Surg Technol Int"},{"issue":"11","key":"pone.0274800.ref012","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.2460\/javma.229.11.1756","article-title":"Effects of caloric restriction and a moderate or intense physiotherapy program for treatment of lameness in overweight dogs with osteoarthritis","volume":"229","author":"E Mlacnik","year":"2006","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"pone.0274800.ref013","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2460\/javma.230.4.514","article-title":"Systematic review of clinical trials of treatments for osteoarthritis in dogs","volume":"230","author":"CL Aragon","year":"2007","journal-title":"J Am Vet Med Assoc"},{"issue":"3","key":"pone.0274800.ref014","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1939-1676.2012.00901.x","article-title":"Systematic review of efficacy of nutraceuticals to alleviate clinical signs of osteoarthritis.","volume":"26","author":"JM Vandeweerd","year":"2012","journal-title":"J Vet Intern Med"},{"issue":"1","key":"pone.0274800.ref015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4314\/ovj.v7i1.6","article-title":"Glucosamine and chondroitin use in canines for osteoarthritis: A review.","volume":"7","author":"A Bhathal","year":"2017","journal-title":"Open Vet J."},{"issue":"14","key":"pone.0274800.ref016","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/vr.164.14.418","article-title":"Systematic review of the management of canine osteoarthritis","volume":"164","author":"RO Sanderson","year":"2009","journal-title":"Vet Rec"},{"issue":"21","key":"pone.0274800.ref017","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/vr.d1021","article-title":"Assessment of veterinary practitioners in the British Isles\u2019 approaches towards the management of canine osteoarthritis","volume":"168","author":"NJ Bound","year":"2011","journal-title":"Vet Rec"},{"issue":"1","key":"pone.0274800.ref018","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1467-2995.2011.00675.x","article-title":"Clinical pharmacology of nonsteroidal anti-inflammatory drugs in dogs","volume":"39","author":"B Kukanich","year":"2012","journal-title":"Vet Anaesth Analg"},{"issue":"1","key":"pone.0274800.ref019","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12917-018-1566-1","article-title":"Six-month safety evaluation of robenacoxib tablets (Onsior\u2122) in dogs after daily oral administrations.","volume":"14","author":"CE Toutain","year":"2018","journal-title":"BMC Vet Res"},{"issue":"3","key":"pone.0274800.ref020","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jvim.13948","article-title":"A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis.","volume":"30","author":"L Rausch-Derra","year":"2016","journal-title":"J Vet Intern Med"},{"issue":"6","key":"pone.0274800.ref021","first-page":"943","article-title":"A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis.","volume":"48","author":"MJ Corral","year":"2021","journal-title":"Vet Anaesth Analg. 2021 Nov"},{"issue":"13","key":"pone.0274800.ref022","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/vr.160.13.427","article-title":"Long-term treatment with carprofen of 805 dogs with osteoarthritis.","volume":"160","author":"S Mansa","year":"2007","journal-title":"Vet Rec"},{"issue":"8","key":"pone.0274800.ref023","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/vr.c97","article-title":"Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis","volume":"166","author":"JF Innes","year":"2010","journal-title":"Vet Rec"},{"issue":"11","key":"pone.0274800.ref024","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/vr.152.11.323","article-title":"Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis","volume":"152","author":"M Moreau","year":"2003","journal-title":"Vet Rec"},{"issue":"3","key":"pone.0274800.ref025","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2460\/ajvr.68.3.258","article-title":"Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs","volume":"68","author":"SP Luna","year":"2007","journal-title":"Am J Vet Res"},{"issue":"5","key":"pone.0274800.ref026","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/jvim.12127","article-title":"Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs","volume":"27","author":"BP Monteiro-Steagall","year":"2013","journal-title":"J Vet Intern Med"},{"issue":"3","key":"pone.0274800.ref027","doi-asserted-by":"crossref","first-page":"e58125","DOI":"10.1371\/journal.pone.0058125","article-title":"Evaluation of construct and criterion validity for the \u2019Liverpool Osteoarthritis in Dogs\u2019 (LOAD) clinical metrology instrument and comparison to two other instruments.","volume":"8","author":"MB Walton","year":"2013","journal-title":"PLoS One."},{"issue":"1","key":"pone.0274800.ref028","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12917-020-02404-5","article-title":"\"You can be blind because of loving them so much\": the impact on owners in the United Kingdom of living with a dog with osteoarthritis.","volume":"16","author":"Z Belshaw","year":"2020","journal-title":"BMC Vet Res"},{"issue":"17","key":"pone.0274800.ref029","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/vr.102352","article-title":"Veterinarians\u2019 attitudes to chronic pain in dogs","volume":"175","author":"A Bell","year":"2014","journal-title":"Vet Rec"},{"issue":"4","key":"pone.0274800.ref030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1748-5827.1999.tb03781.x","article-title":"Compliance with short-term oral antibacterial drug treatment in dogs.","volume":"40","author":"K Grave","year":"1999","journal-title":"J Small Anim Pract."},{"issue":"4","key":"pone.0274800.ref031","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2460\/javma.2005.226.567","article-title":"Evaluation of client compliance with short-term administration of antimicrobials to dogs","volume":"226","author":"VJ Adams","year":"2005","journal-title":"J Am Vet Med Assoc"},{"key":"pone.0274800.ref032","unstructured":"American Animal Hospital Association. Compliance: Taking Quality Care to the Next Level; a Report of the 2009 AAHA Compliance Follow-Up Study. Lakewood, Colo: American Animal Hospital Association, 2009."},{"key":"pone.0274800.ref033","unstructured":"European Commission Union Register of veterinary medicinal products. Daxocox. 2021. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/v270.htm [Accessed on: Jun 15, 2021]."},{"issue":"6","key":"pone.0274800.ref034","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/jvp.12995","article-title":"Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration.","volume":"44","author":"J Homedes","year":"2021","journal-title":"J Vet Pharmacol Ther."},{"issue":"3","key":"pone.0274800.ref035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jvp.13042","article-title":"Selective inhibition of cyclooxygenase-2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood","volume":"45","author":"J Sol\u00e0","year":"2022","journal-title":"J Vet Pharmacol Ther"},{"issue":"1","key":"pone.0274800.ref036","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/vms3.670","article-title":"Pharmacology of enflicoxib, a new coxib drug: Efficacy and dose determination by clinical and pharmacokinetic-guided approach for the treatment of osteoarthritis in dogs based on an acute arthritis induction model","volume":"8","author":"JM Cendr\u00f3s","year":"2022","journal-title":"Vet Med Sci"},{"key":"pone.0274800.ref037","first-page":"e949","article-title":"Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: A 6-week randomised, controlled, blind, multicentre clinical trial","volume":"29","author":"M Salichs","year":"2021","journal-title":"Vet Rec"},{"key":"pone.0274800.ref038","author":"VICH","year":"2000","journal-title":"International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products, Good Clinical Practice"},{"issue":"17","key":"pone.0274800.ref039","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/vr.159.17.547","article-title":"Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis","volume":"159","author":"M Pollmeier","year":"2006","journal-title":"Vet Rec"},{"issue":"23","key":"pone.0274800.ref040","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/vr.d1456","article-title":"Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis","volume":"11168","author":"A Autefage","year":"2011","journal-title":"Vet Rec"},{"issue":"9","key":"pone.0274800.ref041","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1292\/jvms.11-0529","article-title":"Comparison of oral robenacoxib and carprofen for the treatment of osteoarthritis in dogs: a randomized clinical trial","volume":"74","author":"K Edamura","year":"2012","journal-title":"J Vet Med Sci"},{"issue":"11","key":"pone.0274800.ref042","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/vr.102397","article-title":"Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis","volume":"14176","author":"M Payne-Johnson","year":"2015","journal-title":"Vet Rec"},{"issue":"3","key":"pone.0274800.ref043","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/vms3.182","article-title":"Effects of a nutritional supplement in dogs affected by osteoarthritis","volume":"5","author":"N Musco","year":"2019","journal-title":"Vet Med Sci"},{"issue":"6","key":"pone.0274800.ref044","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2460\/ajvr.68.6.631","article-title":"Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis","volume":"68","author":"DC Brown","year":"2007","journal-title":"Am J Vet Res"},{"issue":"8","key":"pone.0274800.ref045","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2460\/javma.233.8.1278","article-title":"Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis","volume":"233","author":"DC Brown","year":"2008","journal-title":"J Am Vet Med Assoc"},{"issue":"5","key":"pone.0274800.ref046","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2885.2010.01165.x","article-title":"The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs","volume":"33","author":"SR Cox","year":"2010","journal-title":"J Vet Pharmacol Ther"},{"key":"pone.0274800.ref047","unstructured":"VICH 2007 International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products, GL24 on pharmacovigilance of veterinary medicinal products: management of adverse event reports (AERs) October 2007 for implementation by 31st December 2015."},{"key":"pone.0274800.ref048","unstructured":"EMA 2018. EMA\/CVMP\/PhVWP\/10418\/2009-Rev.10 Committee for Medicinal Products for Veterinary Use (CVMP) Combined VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products. 21 June 2018."},{"key":"pone.0274800.ref049","unstructured":"EMA 2013 EMA\/CVMP\/PhVWP\/552\/2003 \u2013Rev.1 Committee for Medicinal Products for Veterinary Use (CVMP) Recommendation on harmonising the approach to causality assessment for adverse events to veterinary medicinal products. 10 October 2013."},{"key":"pone.0274800.ref050","unstructured":"NTA 2011. VOLUME 9B of The Rules Governing Medicinal Products in the European Union\u2013Guidelines on Pharmacovigilance for Medicinal Products for Veterinary Use. October 2011."},{"key":"pone.0274800.ref051","unstructured":"EMA 2021. EMA\/CVMP\/EWP\/1061\/2001-Rev.1* Committee for Medicinal Products for Veterinary Use (CVMP) Guideline for the conduct of efficacy studies for nonsteroidal anti-inflammatory drugs. 23 July 2021."},{"key":"pone.0274800.ref052","unstructured":"EMA 2022. EMA\/CVMP\/EWP\/81976\/2010 Rev.1 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on statistical principles for clinical trials for veterinary medicinal products (pharmaceuticals)\u2014Rev. 1. 28\/01\/2022."},{"issue":"10","key":"pone.0274800.ref053","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.2460\/javma.241.10.1314","article-title":"Caregiver placebo effect for dogs with lameness from osteoarthritis","volume":"241","author":"MG Conzemius","year":"2012","journal-title":"J Am Vet Med Assoc"},{"key":"pone.0274800.ref054","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/1746-6148-8-185","article-title":"Effect of analgesic therapy on clinical outcome measures in a randomized controlled trial using client-owned dogs with hip osteoarthritis","volume":"8","author":"S Malek","year":"2012","journal-title":"BMC Vet Res"},{"issue":"12","key":"pone.0274800.ref055","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2460\/ajvr.74.12.1467","article-title":"Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis","volume":"74","author":"DC Brown","year":"2013","journal-title":"Am J Vet Res"},{"issue":"5","key":"pone.0274800.ref056","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3415\/VCOT-17-02-0020","article-title":"Efficacy of an oral nutraceutical for the treatment of canine osteoarthritis. A double-blind, randomized, placebo-controlled prospective clinical trial.","volume":"30","author":"RM Scott","year":"2017","journal-title":"Vet Comp Orthop Traumatol."},{"issue":"17","key":"pone.0274800.ref057","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/vr.148.17.525","article-title":"Development of a behaviour-based scale to measure acute pain in dogs","volume":"148","author":"L Holton","year":"2001","journal-title":"Vet Rec"},{"issue":"11","key":"pone.0274800.ref058","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2460\/javma.2003.222.1552","article-title":"Evaluation of methods for assessment of pain associated with chronic osteoarthritis in dogs","volume":"222","author":"AK Hielm-Bj\u00f6rkman","year":"2003","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"pone.0274800.ref059","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5326\/JAAHA-MS-7292","article-title":"2022 AAHA Pain Management Guidelines for Dogs and Cats.","volume":"58","author":"ME Gruen","year":"2022","journal-title":"J Am Anim Hosp Assoc"},{"issue":"4","key":"pone.0274800.ref060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2460\/ajvr.75.4.353","article-title":"Erratum to Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis.","volume":"75","author":"DC Brown","year":"2014","journal-title":"Am J Vet Res"},{"issue":"5","key":"pone.0274800.ref061","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2460\/ajvr.72.5.601","article-title":"Reliability and validity of a visual analogue scale used by owners to measure chronic pain attributable to osteoarthritis in their dogs","volume":"72","author":"AK Hielm-Bj\u00f6rkman","year":"2011","journal-title":"Am J Vet Res"},{"issue":"3","key":"pone.0274800.ref062","first-page":"237","article-title":"Guidelines for safe and effective use of NSAIDs in dogs.","volume":"6","author":"BD Lascelles","year":"2005","journal-title":"Vet Ther."},{"issue":"11","key":"pone.0274800.ref063","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/vr.102435","article-title":"Mavacoxib and meloxicam for canine osteoarthritis: a randomised clinical comparator trial","volume":"175","author":"MB Walton","year":"2014","journal-title":"Vet Rec"},{"issue":"4","key":"pone.0274800.ref064","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cvsm.2012.04.007","article-title":"Geriatric veterinary pharmacology","volume":"42","author":"B. Kukanich","year":"2012","journal-title":"Vet Clin North Am Small Anim Pract"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T13:34:32Z","timestamp":1663680872000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274800"}},"subtitle":[],"editor":[{"given":"Yasunori","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":64,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0274800","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}